Yael Gelfand

422 total citations
18 papers, 345 citations indexed

About

Yael Gelfand is a scholar working on Immunology, Hematology and Oncology. According to data from OpenAlex, Yael Gelfand has authored 18 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 14 papers in Hematology and 3 papers in Oncology. Recurrent topics in Yael Gelfand's work include Hematopoietic Stem Cell Transplantation (14 papers), Immune Cell Function and Interaction (12 papers) and T-cell and B-cell Immunology (7 papers). Yael Gelfand is often cited by papers focused on Hematopoietic Stem Cell Transplantation (14 papers), Immune Cell Function and Interaction (12 papers) and T-cell and B-cell Immunology (7 papers). Yael Gelfand collaborates with scholars based in Israel, United States and Netherlands. Yael Gelfand's co-authors include Shoshana Morecki, Shimon Slavin, S Slavin, Arnon Nagler, Horst Lindhofer, E Naparstek, G. Váradi, Reuven Or, Aliza Ackerstein and Soumya Panigrahi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Immunology Immunotherapy.

In The Last Decade

Yael Gelfand

18 papers receiving 321 citations

Peers

Countries citing papers authored by Yael Gelfand

Since Specialization

Citations

This map shows the geographic impact of Yael Gelfand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yael Gelfand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yael Gelfand more than expected).

Fields of papers citing papers by Yael Gelfand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yael Gelfand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yael Gelfand. The network helps show where Yael Gelfand may publish in the future.

Co-authorship network of co-authors of Yael Gelfand

This figure shows the co-authorship network connecting the top 25 collaborators of Yael Gelfand. A scholar is included among the top collaborators of Yael Gelfand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yael Gelfand. Yael Gelfand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses 2011 ·Bone Marrow Transplantation ·Shoshana Morecki, Yael Gelfand, (unknown), (unknown), (unknown), Idit Sagiv-Barfi, S Slavin	2
2	Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators 2009 ·Biology of Blood and Marrow Transplantation ·Shoshana Morecki, (unknown), Yael Gelfand, (unknown), Shimon Slavin	5
3	Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody 2008 ·Experimental Hematology ·Shoshana Morecki, Horst Lindhofer, (unknown), Yael Gelfand, Peter Ruf, Shimon Slavin	32
4	CpG-Induced Myeloid CD11b+Gr-1+ Cells Efficiently Suppress T Cell–Mediated Immunoreactivity and Graft-Versus-Host Disease in a Murine Model of Allogeneic Cell Therapy 2008 ·Biology of Blood and Marrow Transplantation ·Shoshana Morecki, Yael Gelfand, (unknown), (unknown), (unknown), Shimon Slavin	31
5	Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients 2007 ·Experimental Hematology ·Shoshana Morecki, (unknown), Yael Gelfand, (unknown), Shimon Slavin	7
6	Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes 2005 ·Blood ·Shoshana Morecki, Horst Lindhofer, (unknown), Yael Gelfand, Shimon Slavin	22
7	A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation 2004 ·Experimental Hematology ·Soumya Panigrahi, Shoshana Morecki, (unknown), Yael Gelfand, (unknown), Shimon Slavin	9
8	Effect of KRN7000 on induced graft-vs-host disease 2004 ·Experimental Hematology ·Shoshana Morecki, Soumya Panigrahi, Galina Pizov, (unknown), Yael Gelfand, (unknown), Shimon Slavin	33
9	Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation 2004 ·Journal of Clinical Oncology ·Shimon Slavin, Shoshana Morecki, M Y Shapira, Menachem Bitan, S Samuel, Aliza Ackerstein, Yael Gelfand, Igor Resnick, R. Or	8
10	Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect 2004 ·Biology of Blood and Marrow Transplantation ·Shoshana Morecki, (unknown), Yael Gelfand, (unknown), Shimon Slavin	11
11	Treatment of Resistant Leukemia by rIL-2 Activated NK Cells in Recipients of HLA Matched and Haploidentically Mismatched Stem Cell Allografts while Avoiding GVHD. 2004 ·Blood ·Shimon Slavin, Reuven Or, Memet Aker, Michael Y. Shapira, Igor Resnick, Menachem Bitan, (unknown), (unknown), Simcha Samuel, Yael Gelfand, (unknown), (unknown), Aliza Ackerstein, Shoshana Morecki	6
12	Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer 2002 ·PubMed ·Soumya Panigrahi, (unknown), Yael Gelfand, Lucia Schuger, Shimon Slavin, Shoshana Morecki	4
13	Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes 2001 ·Bone Marrow Transplantation ·S Slavin, Aliza Ackerstein, Shoshana Morecki, Yael Gelfand, Gabriel Cividalli	28
14	Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma 2001 ·Journal of Immunotherapy ·Shoshana Morecki, (unknown), Yael Gelfand, (unknown), Shimon Slavin	31
15	Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen 2001 ·Bone Marrow Transplantation ·Shoshana Morecki, Yael Gelfand, Arnon Nagler, Reuven Or, E Naparstek, G. Váradi, Dan Engelhard, (unknown), S Slavin	66
16	Immune reconstitution Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen 2001 ·Shoshana Morecki, Yael Gelfand, Arnon Nagler, E Naparstek, G. Váradi, S Slavin	10
17	Induction of antitumor immunity by indomethacin 2000 ·Cancer Immunology Immunotherapy ·(unknown), Yael Gelfand, (unknown), Esther Shohami, Victoria Trembovler, Shimon Slavin	29
18	Activated Long-Term Peripheral Blood Cultures as Preparation for Adoptive Alloreactive Cell Therapy in Cancer Patients 1997 ·Journal of Hematotherapy ·Shoshana Morecki, Yael Gelfand, (unknown), Arnon Nagler, Reba Condiotti, (unknown), Aliza Ackerstein, Shimon Slavin	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact